Pharmaceutical Drug Bids
•Download as PPTX, PDF•
0 likes•8 views
Pharmaceutical companies bid on sales to medical facilities. This company wanted to use AI to increase their percentage of wins.
Report
Share
Report
Share
Recommended
Competition and Pharmaceuticals - Aidan Hollis - 2014 OECD Global Forum on Co...
Competition and Pharmaceuticals - Aidan Hollis - 2014 OECD Global Forum on Co...OECD Directorate for Financial and Enterprise Affairs
This presentation by Aidan Hollis was made at the 2014 Global Forum on Competition (27-28 February) during the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforumCompetition and Pharmaceuticals - Farasat Bokhari - 2014 OECD Global Forum on...
Competition and Pharmaceuticals - Farasat Bokhari - 2014 OECD Global Forum on...OECD Directorate for Financial and Enterprise Affairs
This presentation by Farasat Bokhari was made at the 2014 Global Forum on Competition (27-28 February) at the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforumWhat if: A sliding scale were used to reimburse generic drugs to effectively ...
1) Currently, Ontario sets generic drug prices as a fixed percentage of the brand name drug price, but this percentage is arbitrary and may be too high or too low for different drugs.
2) While there is competition between generic drug manufacturers, retail prices remain high because pharmacies capture large margins within the allowed price ceilings.
3) The proposal is for a "descending royalty" system where the generic price is determined by the number of manufacturers, with the goal of driving prices down towards marginal cost through competition like the brand drug market.
Competition and Pharmaceuticals - Adrian Majumdar - 2014 OECD Global Forum on...
Competition and Pharmaceuticals - Adrian Majumdar - 2014 OECD Global Forum on...OECD Directorate for Financial and Enterprise Affairs
This presentation by Adrian Majumdar was made at the 2014 Global Forum on Competition (27-28 February) at the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforum
Competition and Pharmaceuticals - Pradeep Mehta - 2014 OECD Global Forum on C...
Competition and Pharmaceuticals - Pradeep Mehta - 2014 OECD Global Forum on C...OECD Directorate for Financial and Enterprise Affairs
This presentation by Pradeep Mehta was made at the 2014 Global Forum on Competition (27-28 February) during the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforumEshaan merck evaluation
Merck faces challenges with growth and is expected to pursue cost efficiencies, mergers and acquisitions with other large pharmaceutical companies, biotech firms, midsize pharmaceutical players, and generics manufacturers. Any new products must be carefully launched and marketed to avoid controversial safety issues like those with Vioxx. Regulatory bodies should be provided drug samples for testing after the drug's effects have been thoroughly evaluated in-house to avoid approval delays for future drugs. Merck may also seek to extend product patent durations where possible.
OptimizerRX Investor Presentation
The document discusses Optimizerx's SampleMD software, which allows doctors to electronically send drug sample vouchers and coupons to patients directly from their EHR systems. This helps doctors assist more patients and drug companies market to doctors in a compliant way. SampleMD partners with large EHR vendors like Allscripts to reach over 200,000 doctors. It generates revenue by charging drug companies to offer samples/coupons and receiving fees for every one used. The business model is highly leveraged as growing adoption could enable high volumes of incremental revenue with modest overhead costs.
Pharmaceuticals – KYLE – November 2018 OECD discussion
Pharmaceuticals – KYLE – November 2018 OECD discussionOECD Directorate for Financial and Enterprise Affairs
This presentation by Margaret KYLE, Professor of Economics, MINES Paris Tech, was made during the discussion “Excessive Pricing in Pharmaceuticals” held at the 130th meeting of the OECD Competition Committee on 28 November 2018. More papers and presentations on the topic can be found out at oe.cd/exph.Recommended
Competition and Pharmaceuticals - Aidan Hollis - 2014 OECD Global Forum on Co...
Competition and Pharmaceuticals - Aidan Hollis - 2014 OECD Global Forum on Co...OECD Directorate for Financial and Enterprise Affairs
This presentation by Aidan Hollis was made at the 2014 Global Forum on Competition (27-28 February) during the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforumCompetition and Pharmaceuticals - Farasat Bokhari - 2014 OECD Global Forum on...
Competition and Pharmaceuticals - Farasat Bokhari - 2014 OECD Global Forum on...OECD Directorate for Financial and Enterprise Affairs
This presentation by Farasat Bokhari was made at the 2014 Global Forum on Competition (27-28 February) at the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforumWhat if: A sliding scale were used to reimburse generic drugs to effectively ...
1) Currently, Ontario sets generic drug prices as a fixed percentage of the brand name drug price, but this percentage is arbitrary and may be too high or too low for different drugs.
2) While there is competition between generic drug manufacturers, retail prices remain high because pharmacies capture large margins within the allowed price ceilings.
3) The proposal is for a "descending royalty" system where the generic price is determined by the number of manufacturers, with the goal of driving prices down towards marginal cost through competition like the brand drug market.
Competition and Pharmaceuticals - Adrian Majumdar - 2014 OECD Global Forum on...
Competition and Pharmaceuticals - Adrian Majumdar - 2014 OECD Global Forum on...OECD Directorate for Financial and Enterprise Affairs
This presentation by Adrian Majumdar was made at the 2014 Global Forum on Competition (27-28 February) at the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforum
Competition and Pharmaceuticals - Pradeep Mehta - 2014 OECD Global Forum on C...
Competition and Pharmaceuticals - Pradeep Mehta - 2014 OECD Global Forum on C...OECD Directorate for Financial and Enterprise Affairs
This presentation by Pradeep Mehta was made at the 2014 Global Forum on Competition (27-28 February) during the session on competition issues in the distribution of pharmaceuticals. Find out more at http://www.oecd.org/competition/globalforumEshaan merck evaluation
Merck faces challenges with growth and is expected to pursue cost efficiencies, mergers and acquisitions with other large pharmaceutical companies, biotech firms, midsize pharmaceutical players, and generics manufacturers. Any new products must be carefully launched and marketed to avoid controversial safety issues like those with Vioxx. Regulatory bodies should be provided drug samples for testing after the drug's effects have been thoroughly evaluated in-house to avoid approval delays for future drugs. Merck may also seek to extend product patent durations where possible.
OptimizerRX Investor Presentation
The document discusses Optimizerx's SampleMD software, which allows doctors to electronically send drug sample vouchers and coupons to patients directly from their EHR systems. This helps doctors assist more patients and drug companies market to doctors in a compliant way. SampleMD partners with large EHR vendors like Allscripts to reach over 200,000 doctors. It generates revenue by charging drug companies to offer samples/coupons and receiving fees for every one used. The business model is highly leveraged as growing adoption could enable high volumes of incremental revenue with modest overhead costs.
Pharmaceuticals – KYLE – November 2018 OECD discussion
Pharmaceuticals – KYLE – November 2018 OECD discussionOECD Directorate for Financial and Enterprise Affairs
This presentation by Margaret KYLE, Professor of Economics, MINES Paris Tech, was made during the discussion “Excessive Pricing in Pharmaceuticals” held at the 130th meeting of the OECD Competition Committee on 28 November 2018. More papers and presentations on the topic can be found out at oe.cd/exph.Adherence product plan v6.1
This presentation details a Go-To-Market plan for a medication adherence service sold to pharmaceutical companies
PBM Rebate Modeling and Management
The document discusses the complexities of managing pharmaceutical rebate contracts and describes the features of AdvanceRebate, a software tool for modeling, managing, and optimizing rebate contracts. AdvanceRebate allows users to model rebate contract parameters, automatically build market baskets, compare contracts, generate projections and alerts, and facilitate tier swapping to maximize savings. The tool provides increased revenue, savings, transparency and streamlined workflow for managing the numerous intricacies of rebate contracts.
Emerging Pharma Business & Operational Models
The document discusses emerging business and operational models in the pharmaceutical industry. It notes that the traditional vertically integrated model is shifting to a more fragmented model. It also discusses factors driving changes like rising costs and competition. The document analyzes current blockbuster and niche models and potential future models involving more specialization. It proposes a "progressive drug development model" to reduce risks and costs through targeted development.
Next generation commercial capabilities
This document outlines a vision for next-generation commercial capabilities within the pharmaceutical industry. It discusses the paradigm shift occurring as healthcare markets evolve more rapidly, driving the need for pharmaceutical companies to innovate their commercial models to navigate increasing complexity and costs. It proposes a collaborative model where companies leverage external partners' expertise in analytics, technology, and skills alongside internal assets to build commercial centers of excellence. These centers of excellence would standardize processes while clustering subject matter expertise to develop capabilities as a strategic differentiator and recognize efficiencies over time. The goal is to provide faster access to insights from vast and diverse healthcare data sources to implement locally relevant solutions on a global scale.
Maximizing ROI The Science of Targeted Pharma Engagements.pdf
In the ever-evolving world of pharmaceuticals, achieving a high return on investment (ROI) is a primary goal. The pharmaceutical industry is increasingly turning to targeted engagements to attain this objective. This whitepaper delves into the science behind targeted pharmaceutical engagements, exploring the strategies, technologies, and best practices that can maximize ROI while improving patient outcomes. By understanding the intricacies of targeted engagements, pharmaceutical companies can navigate the industry's complexities, enhance their market presence, and deliver value to patients and stakeholders.
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowseOffice of Health Economics
This presentation looks at ways in which governments can set prices, including “cost plus”, value, and the external referencing of prices elsewhere. It looks at the role that competition can play in keeping down prices. In that context it briefly discusses pricing proposals being considered in Malaysia. It makes the case for using HTA to inform pricing decisions.
Adrian TowseApplication of BI in pharmaceutical industry
A whitepaper from MicroStrategy Inc. on the application of BI in the pharma industry. Source: open internet
Evolving Operational Business Model in Pharmaceutical Industry
The pharmaceutical industry is changing its business and operational models due to various pressures. The current model of vertical integration from research to pharmacy is shifting to a more fragmented model. Key drivers include rising costs, price pressures, increased regulation, and patent expirations. The industry must address these issues to sustain growth and profits. Alternative business strategies are needed due to instability in the current blockbuster drug model, which relies on a few highly profitable drugs to offset research and development costs.
Pharmacy Benefit Managers
Pharmacy Benefit Managers (PBMs) are professionals that administer prescription drug plans for payers, employers, and CMS programs .
Pharma Sales Crediting: Incentives for Accurate & Compliant Processes
The document discusses the complex process of incentivizing pharmaceutical sales representatives. It notes that designing sales incentive programs involves establishing quotas, measuring performance against quotas, and ensuring accurate sales data collection and mapping to territories while complying with regulations. An effective sales crediting process requires mapping prescription data to territories, applying business rules to remain compliant, and conducting quality checks to avoid errors and lawsuits. Key challenges include mapping scripts to reps, handling roster changes, and clearly defining rules to demonstrate fair compensation and avoid litigation.
Strategies to Enhance Pharmacy Benefit Management
This document provides strategies for self-insured employers to better manage pharmacy benefit costs and performance. It recommends marshaling in-house expertise to better understand how PBMs generate profits through various pricing strategies. It also suggests replacing traditional RFP processes with reverse auctions to drive more competitive pricing from PBMs, particularly for specialty drugs. Overall, the document aims to educate employers on optimizing PBM contracts and strategies to control rising prescription drug costs.
ConnectureDRX - Medicare Shopping, Quoting & Enrollment Platform
This document describes PlanCompare ONE, a platform from Connecture that provides Medicare plan shopping, quoting, and enrollment capabilities. It has the largest Medicare market share and supports over 100 health plans nationwide. The platform provides highly accurate drug pricing and total cost estimates. It allows flexible delivery models and supports brokers, call centers, and direct-to-consumer audiences through an omni-channel approach. The platform is compliant, configurable, and integrated with CRM systems to improve the consumer experience and increase conversions and retention.
Price-volume strategies and differential pricing in Asia Pacific
To succeed in this dynamic healthcare industry, price-volume strategies require a concerted effort from all parts of the business and close alignment with the overall strategy. Learn more about the strategies from some successful case studies in the Asia-Pacific region.
Pharmaceutical Supply Chains Require New Operational and Technology Models to...
The pharmaceutical supply chain requires new operational and technology models to enable collaboration and efficiency. Pharmaceutical companies face slowed growth, industry pressures, and declining margins. They must embrace demand-chain thinking and cloud solutions to share real-time data with partners. This will help manage unpredictable demand, gain inventory visibility, and serve diverse markets. Cloud platforms can provide a common space for stakeholders to connect and share data, fostering transparency and accountability.
Pfizer and Merck cooperate to fight cancer
Biotech revolution changed the pharmaceutical industry, triggering a wave of risky collaborations between rivals. Based on the research findings, we answer the question why cooperation in the field of immuno-oncology is a better strategy for Pfizer and Merck KGaA, which aim to achieve competitive advantage quickly and with minimum effort. Combining their assets and core expertise companies realize benefits of greater size and variety in the conduct of research, development and commercializing of their new breakthrough therapy for cancer treatment.
CBO’s Model of New Drug Development
Presentation by Chris Adams, an analyst in CBO’s Health Analysis Division, to the Dartmouth Institute for Health Policy & Clinical Practice.
Machine Learning to Control Medicare Prescription Drug Costs
This project used Gradient Boosting to recognize physicians who have much higher prescription drug costs compared to their predicted cost. The Coefficient of Determination using this algorithm was .664. Additionally the accuracy of the model is such that 79.5% of physicians were no more than 40% above their predicted drug costs, while 88.2% were no more than 60% above their predicted costs.
AI - The Next Frontier for Connected Pharma
Big pharma has long been challenged with siloed data resulting from drug discovery information, clinical trial results and product marketing research stored separately in decade-old legacy systems. Thus, the pharmaceutical industry is ripe for the actionable insights offered by these advances to offset the growing costs of drug discovery while still meeting the demands of a value-based care model. It is time for a connected approach in the pharmaceutical industry.
A review of marketing
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies that require long-term treatment. This allows companies to build more stable customer bases. The document also outlines some of the challenges companies face, such as increased competition, high costs of research and development, and complex decision-making processes involving doctors, patients, and other stakeholders. It discusses two common business models - the "super core model" involving a small number of highly successful chronic drugs, and the "core model" involving marketing a larger number of acute drugs.
A review of marketing
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies. This represents a long-term strategy change as chronic therapies require doctors to prescribe the same drugs for longer periods. The document also outlines some of the challenges pharmaceutical companies face in marketing to different customers in the supply chain from doctors to patients. It discusses strategies around patents, research and development, and pursuing either a "super core" model focused on a small number of chronic drugs or a "core" model marketing more acute drugs.
CrowdANALYTIX Case Studies
CrowdANALYTIX used machine learning models to analyze historical flight data and identify specific guidelines for reducing fuel costs in short-haul flights by 2.7%, such as determining the optimal angle of climb and cruising speed for enhanced fuel efficiency. The models were developed by extracting relevant features from raw flight data and identifying the most accurate in predicting fuel efficiency.
Predicting Flight Delays
Flight delays can be unpredictable, and therefore costly. This airline wanted to use AI to accurately predict flight delays and save on time and costs.
More Related Content
Similar to Pharmaceutical Drug Bids
Adherence product plan v6.1
This presentation details a Go-To-Market plan for a medication adherence service sold to pharmaceutical companies
PBM Rebate Modeling and Management
The document discusses the complexities of managing pharmaceutical rebate contracts and describes the features of AdvanceRebate, a software tool for modeling, managing, and optimizing rebate contracts. AdvanceRebate allows users to model rebate contract parameters, automatically build market baskets, compare contracts, generate projections and alerts, and facilitate tier swapping to maximize savings. The tool provides increased revenue, savings, transparency and streamlined workflow for managing the numerous intricacies of rebate contracts.
Emerging Pharma Business & Operational Models
The document discusses emerging business and operational models in the pharmaceutical industry. It notes that the traditional vertically integrated model is shifting to a more fragmented model. It also discusses factors driving changes like rising costs and competition. The document analyzes current blockbuster and niche models and potential future models involving more specialization. It proposes a "progressive drug development model" to reduce risks and costs through targeted development.
Next generation commercial capabilities
This document outlines a vision for next-generation commercial capabilities within the pharmaceutical industry. It discusses the paradigm shift occurring as healthcare markets evolve more rapidly, driving the need for pharmaceutical companies to innovate their commercial models to navigate increasing complexity and costs. It proposes a collaborative model where companies leverage external partners' expertise in analytics, technology, and skills alongside internal assets to build commercial centers of excellence. These centers of excellence would standardize processes while clustering subject matter expertise to develop capabilities as a strategic differentiator and recognize efficiencies over time. The goal is to provide faster access to insights from vast and diverse healthcare data sources to implement locally relevant solutions on a global scale.
Maximizing ROI The Science of Targeted Pharma Engagements.pdf
In the ever-evolving world of pharmaceuticals, achieving a high return on investment (ROI) is a primary goal. The pharmaceutical industry is increasingly turning to targeted engagements to attain this objective. This whitepaper delves into the science behind targeted pharmaceutical engagements, exploring the strategies, technologies, and best practices that can maximize ROI while improving patient outcomes. By understanding the intricacies of targeted engagements, pharmaceutical companies can navigate the industry's complexities, enhance their market presence, and deliver value to patients and stakeholders.
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowseOffice of Health Economics
This presentation looks at ways in which governments can set prices, including “cost plus”, value, and the external referencing of prices elsewhere. It looks at the role that competition can play in keeping down prices. In that context it briefly discusses pricing proposals being considered in Malaysia. It makes the case for using HTA to inform pricing decisions.
Adrian TowseApplication of BI in pharmaceutical industry
A whitepaper from MicroStrategy Inc. on the application of BI in the pharma industry. Source: open internet
Evolving Operational Business Model in Pharmaceutical Industry
The pharmaceutical industry is changing its business and operational models due to various pressures. The current model of vertical integration from research to pharmacy is shifting to a more fragmented model. Key drivers include rising costs, price pressures, increased regulation, and patent expirations. The industry must address these issues to sustain growth and profits. Alternative business strategies are needed due to instability in the current blockbuster drug model, which relies on a few highly profitable drugs to offset research and development costs.
Pharmacy Benefit Managers
Pharmacy Benefit Managers (PBMs) are professionals that administer prescription drug plans for payers, employers, and CMS programs .
Pharma Sales Crediting: Incentives for Accurate & Compliant Processes
The document discusses the complex process of incentivizing pharmaceutical sales representatives. It notes that designing sales incentive programs involves establishing quotas, measuring performance against quotas, and ensuring accurate sales data collection and mapping to territories while complying with regulations. An effective sales crediting process requires mapping prescription data to territories, applying business rules to remain compliant, and conducting quality checks to avoid errors and lawsuits. Key challenges include mapping scripts to reps, handling roster changes, and clearly defining rules to demonstrate fair compensation and avoid litigation.
Strategies to Enhance Pharmacy Benefit Management
This document provides strategies for self-insured employers to better manage pharmacy benefit costs and performance. It recommends marshaling in-house expertise to better understand how PBMs generate profits through various pricing strategies. It also suggests replacing traditional RFP processes with reverse auctions to drive more competitive pricing from PBMs, particularly for specialty drugs. Overall, the document aims to educate employers on optimizing PBM contracts and strategies to control rising prescription drug costs.
ConnectureDRX - Medicare Shopping, Quoting & Enrollment Platform
This document describes PlanCompare ONE, a platform from Connecture that provides Medicare plan shopping, quoting, and enrollment capabilities. It has the largest Medicare market share and supports over 100 health plans nationwide. The platform provides highly accurate drug pricing and total cost estimates. It allows flexible delivery models and supports brokers, call centers, and direct-to-consumer audiences through an omni-channel approach. The platform is compliant, configurable, and integrated with CRM systems to improve the consumer experience and increase conversions and retention.
Price-volume strategies and differential pricing in Asia Pacific
To succeed in this dynamic healthcare industry, price-volume strategies require a concerted effort from all parts of the business and close alignment with the overall strategy. Learn more about the strategies from some successful case studies in the Asia-Pacific region.
Pharmaceutical Supply Chains Require New Operational and Technology Models to...
The pharmaceutical supply chain requires new operational and technology models to enable collaboration and efficiency. Pharmaceutical companies face slowed growth, industry pressures, and declining margins. They must embrace demand-chain thinking and cloud solutions to share real-time data with partners. This will help manage unpredictable demand, gain inventory visibility, and serve diverse markets. Cloud platforms can provide a common space for stakeholders to connect and share data, fostering transparency and accountability.
Pfizer and Merck cooperate to fight cancer
Biotech revolution changed the pharmaceutical industry, triggering a wave of risky collaborations between rivals. Based on the research findings, we answer the question why cooperation in the field of immuno-oncology is a better strategy for Pfizer and Merck KGaA, which aim to achieve competitive advantage quickly and with minimum effort. Combining their assets and core expertise companies realize benefits of greater size and variety in the conduct of research, development and commercializing of their new breakthrough therapy for cancer treatment.
CBO’s Model of New Drug Development
Presentation by Chris Adams, an analyst in CBO’s Health Analysis Division, to the Dartmouth Institute for Health Policy & Clinical Practice.
Machine Learning to Control Medicare Prescription Drug Costs
This project used Gradient Boosting to recognize physicians who have much higher prescription drug costs compared to their predicted cost. The Coefficient of Determination using this algorithm was .664. Additionally the accuracy of the model is such that 79.5% of physicians were no more than 40% above their predicted drug costs, while 88.2% were no more than 60% above their predicted costs.
AI - The Next Frontier for Connected Pharma
Big pharma has long been challenged with siloed data resulting from drug discovery information, clinical trial results and product marketing research stored separately in decade-old legacy systems. Thus, the pharmaceutical industry is ripe for the actionable insights offered by these advances to offset the growing costs of drug discovery while still meeting the demands of a value-based care model. It is time for a connected approach in the pharmaceutical industry.
A review of marketing
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies that require long-term treatment. This allows companies to build more stable customer bases. The document also outlines some of the challenges companies face, such as increased competition, high costs of research and development, and complex decision-making processes involving doctors, patients, and other stakeholders. It discusses two common business models - the "super core model" involving a small number of highly successful chronic drugs, and the "core model" involving marketing a larger number of acute drugs.
A review of marketing
The document discusses marketing strategies used by pharmaceutical companies. It notes that companies are shifting from acute therapies to focusing more on chronic therapies. This represents a long-term strategy change as chronic therapies require doctors to prescribe the same drugs for longer periods. The document also outlines some of the challenges pharmaceutical companies face in marketing to different customers in the supply chain from doctors to patients. It discusses strategies around patents, research and development, and pursuing either a "super core" model focused on a small number of chronic drugs or a "core" model marketing more acute drugs.
Similar to Pharmaceutical Drug Bids (20)
Maximizing ROI The Science of Targeted Pharma Engagements.pdf
Maximizing ROI The Science of Targeted Pharma Engagements.pdf
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian Towse
Evolving Operational Business Model in Pharmaceutical Industry
Evolving Operational Business Model in Pharmaceutical Industry
Pharma Sales Crediting: Incentives for Accurate & Compliant Processes
Pharma Sales Crediting: Incentives for Accurate & Compliant Processes
ConnectureDRX - Medicare Shopping, Quoting & Enrollment Platform
ConnectureDRX - Medicare Shopping, Quoting & Enrollment Platform
Price-volume strategies and differential pricing in Asia Pacific
Price-volume strategies and differential pricing in Asia Pacific
Pharmaceutical Supply Chains Require New Operational and Technology Models to...
Pharmaceutical Supply Chains Require New Operational and Technology Models to...
Machine Learning to Control Medicare Prescription Drug Costs
Machine Learning to Control Medicare Prescription Drug Costs
More from KatharineStevenson
CrowdANALYTIX Case Studies
CrowdANALYTIX used machine learning models to analyze historical flight data and identify specific guidelines for reducing fuel costs in short-haul flights by 2.7%, such as determining the optimal angle of climb and cruising speed for enhanced fuel efficiency. The models were developed by extracting relevant features from raw flight data and identifying the most accurate in predicting fuel efficiency.
Predicting Flight Delays
Flight delays can be unpredictable, and therefore costly. This airline wanted to use AI to accurately predict flight delays and save on time and costs.
Pharmaceutical Trials
Phase III clinical drug trials are costly and inefficient. This pharmaceutical company used AI to reduce costs by up to 12%.
Healthcare Automation
A leading healthcare provider wanted to use AI to optimize the utilization of their facilities and maintain consistency of care.
Automating Discounting Strategies
A Japanese retailer leveraged AI to automate their discounting strategies and processes, standardizing across stores and achieving 630% ROI on their AI investment.
Short-Haul Flights
Short-haul flights can be energy inefficient, and therefore costly. One company looked for an AI-driven solution.
Automotive Performance
This document discusses how an AI company used data from motorbikes to improve performance. They analyzed telemetry, biometric, and GPS data to build models predicting bike performance. The models identified design parameters that could be optimized, such as factors sensitive to operator conditions and courses, improving performance over 4%.
Cement Manufacturing
A top global cement manufacturer found that they were wasting product because they couldn't quality test early in their process. They turned to AI to solve the problem.
More from KatharineStevenson (8)
Recently uploaded
ViewShift: Hassle-free Dynamic Policy Enforcement for Every Data Lake
Dynamic policy enforcement is becoming an increasingly important topic in today’s world where data privacy and compliance is a top priority for companies, individuals, and regulators alike. In these slides, we discuss how LinkedIn implements a powerful dynamic policy enforcement engine, called ViewShift, and integrates it within its data lake. We show the query engine architecture and how catalog implementations can automatically route table resolutions to compliance-enforcing SQL views. Such views have a set of very interesting properties: (1) They are auto-generated from declarative data annotations. (2) They respect user-level consent and preferences (3) They are context-aware, encoding a different set of transformations for different use cases (4) They are portable; while the SQL logic is only implemented in one SQL dialect, it is accessible in all engines.
#SQL #Views #Privacy #Compliance #DataLake
一比一原版(UCSB文凭证书)圣芭芭拉分校毕业证如何办理
毕业原版【微信:176555708】【(UCSB毕业证书)圣芭芭拉分校毕业证】【微信:176555708】成绩单、外壳、offer、留信学历认证（永久存档真实可查）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【我们承诺采用的是学校原版纸张（纸质、底色、纹路），我们拥有全套进口原装设备，特殊工艺都是采用不同机器制作，仿真度基本可以达到100%，所有工艺效果都可提前给客户展示，不满意可以根据客户要求进行调整，直到满意为止！】
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信176555708】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信176555708】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
留信网服务项目：
1、留学生专业人才库服务（留信分析）
2、国（境）学习人员提供就业推荐信服务
3、留学人员区块链存储服务
→ 【关于价格问题（保证一手价格）】
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
选择实体注册公司办理，更放心，更安全！我们的承诺：客户在留信官方认证查询网站查询到认证通过结果后付款，不成功不收费！
Predictably Improve Your B2B Tech Company's Performance by Leveraging Data
Harness the power of AI-backed reports, benchmarking and data analysis to predict trends and detect anomalies in your marketing efforts.
Peter Caputa, CEO at Databox, reveals how you can discover the strategies and tools to increase your growth rate (and margins!).
From metrics to track to data habits to pick up, enhance your reporting for powerful insights to improve your B2B tech company's marketing.
- - -
This is the webinar recording from the June 2024 HubSpot User Group (HUG) for B2B Technology USA.
Watch the video recording at https://youtu.be/5vjwGfPN9lw
Sign up for future HUG events at https://events.hubspot.com/b2b-technology-usa/
My burning issue is homelessness K.C.M.O.
My burning issue is homelessness in Kansas City, MO
To: Tom Tresser
From: Roger Warren
Learn SQL from basic queries to Advance queries
Dive into the world of data analysis with our comprehensive guide on mastering SQL! This presentation offers a practical approach to learning SQL, focusing on real-world applications and hands-on practice. Whether you're a beginner or looking to sharpen your skills, this guide provides the tools you need to extract, analyze, and interpret data effectively.
Key Highlights:
Foundations of SQL: Understand the basics of SQL, including data retrieval, filtering, and aggregation.
Advanced Queries: Learn to craft complex queries to uncover deep insights from your data.
Data Trends and Patterns: Discover how to identify and interpret trends and patterns in your datasets.
Practical Examples: Follow step-by-step examples to apply SQL techniques in real-world scenarios.
Actionable Insights: Gain the skills to derive actionable insights that drive informed decision-making.
Join us on this journey to enhance your data analysis capabilities and unlock the full potential of SQL. Perfect for data enthusiasts, analysts, and anyone eager to harness the power of data!
#DataAnalysis #SQL #LearningSQL #DataInsights #DataScience #Analytics
Beyond the Basics of A/B Tests: Highly Innovative Experimentation Tactics You...
This webinar will explore cutting-edge, less familiar but powerful experimentation methodologies which address well-known limitations of standard A/B Testing. Designed for data and product leaders, this session aims to inspire the embrace of innovative approaches and provide insights into the frontiers of experimentation!
Experts live - Improving user adoption with AI
Bekijk de slides van onze sessie Enhancing Modern Workplace Efficiency op Experts Live 2024.
一比一原版(Chester毕业证书)切斯特大学毕业证如何办理
毕业原版【微信:41543339】【(Chester毕业证书)切斯特大学毕业证】【微信:41543339】成绩单、外壳、offer、留信学历认证（永久存档真实可查）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【我们承诺采用的是学校原版纸张（纸质、底色、纹路），我们拥有全套进口原装设备，特殊工艺都是采用不同机器制作，仿真度基本可以达到100%，所有工艺效果都可提前给客户展示，不满意可以根据客户要求进行调整，直到满意为止！】
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信41543339】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信41543339】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
留信网服务项目：
1、留学生专业人才库服务（留信分析）
2、国（境）学习人员提供就业推荐信服务
3、留学人员区块链存储服务
→ 【关于价格问题（保证一手价格）】
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
选择实体注册公司办理，更放心，更安全！我们的承诺：客户在留信官方认证查询网站查询到认证通过结果后付款，不成功不收费！
University of New South Wales degree offer diploma Transcript
澳洲UNSW毕业证书制作新南威尔士大学假文凭定制Q微168899991做UNSW留信网教留服认证海牙认证改UNSW成绩单GPA做UNSW假学位证假文凭高仿毕业证申请新南威尔士大学University of New South Wales degree offer diploma Transcript
一比一原版(UCSF文凭证书)旧金山分校毕业证如何办理
毕业原版【微信:176555708】【(UCSF毕业证书)旧金山分校毕业证】【微信:176555708】成绩单、外壳、offer、留信学历认证（永久存档真实可查）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【我们承诺采用的是学校原版纸张（纸质、底色、纹路），我们拥有全套进口原装设备，特殊工艺都是采用不同机器制作，仿真度基本可以达到100%，所有工艺效果都可提前给客户展示，不满意可以根据客户要求进行调整，直到满意为止！】
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信176555708】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信176555708】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
留信网服务项目：
1、留学生专业人才库服务（留信分析）
2、国（境）学习人员提供就业推荐信服务
3、留学人员区块链存储服务
→ 【关于价格问题（保证一手价格）】
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
选择实体注册公司办理，更放心，更安全！我们的承诺：客户在留信官方认证查询网站查询到认证通过结果后付款，不成功不收费！
Intelligence supported media monitoring in veterinary medicine
Media monitoring in veterinary medicien
End-to-end pipeline agility - Berlin Buzzwords 2024
We describe how we achieve high change agility in data engineering by eliminating the fear of breaking downstream data pipelines through end-to-end pipeline testing, and by using schema metaprogramming to safely eliminate boilerplate involved in changes that affect whole pipelines.
A quick poll on agility in changing pipelines from end to end indicated a huge span in capabilities. For the question "How long time does it take for all downstream pipelines to be adapted to an upstream change," the median response was 6 months, but some respondents could do it in less than a day. When quantitative data engineering differences between the best and worst are measured, the span is often 100x-1000x, sometimes even more.
A long time ago, we suffered at Spotify from fear of changing pipelines due to not knowing what the impact might be downstream. We made plans for a technical solution to test pipelines end-to-end to mitigate that fear, but the effort failed for cultural reasons. We eventually solved this challenge, but in a different context. In this presentation we will describe how we test full pipelines effectively by manipulating workflow orchestration, which enables us to make changes in pipelines without fear of breaking downstream.
Making schema changes that affect many jobs also involves a lot of toil and boilerplate. Using schema-on-read mitigates some of it, but has drawbacks since it makes it more difficult to detect errors early. We will describe how we have rejected this tradeoff by applying schema metaprogramming, eliminating boilerplate but keeping the protection of static typing, thereby further improving agility to quickly modify data pipelines without fear.
The Ipsos - AI - Monitor 2024 Report.pdf
According to Ipsos AI Monitor's 2024 report, 65% Indians said that products and services using AI have profoundly changed their daily life in the past 3-5 years.
一比一原版(Glasgow毕业证书)格拉斯哥大学毕业证如何办理
毕业原版【微信:41543339】【(Glasgow毕业证书)格拉斯哥大学毕业证】【微信:41543339】成绩单、外壳、offer、留信学历认证（永久存档真实可查）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【我们承诺采用的是学校原版纸张（纸质、底色、纹路），我们拥有全套进口原装设备，特殊工艺都是采用不同机器制作，仿真度基本可以达到100%，所有工艺效果都可提前给客户展示，不满意可以根据客户要求进行调整，直到满意为止！】
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信41543339】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信41543339】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
留信网服务项目：
1、留学生专业人才库服务（留信分析）
2、国（境）学习人员提供就业推荐信服务
3、留学人员区块链存储服务
→ 【关于价格问题（保证一手价格）】
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
选择实体注册公司办理，更放心，更安全！我们的承诺：客户在留信官方认证查询网站查询到认证通过结果后付款，不成功不收费！
DSSML24_tspann_CodelessGenerativeAIPipelines
Codeless Generative AI Pipelines
(GenAI with Milvus)
https://ml.dssconf.pl/user.html#!/lecture/DSSML24-041a/rate
Discover the potential of real-time streaming in the context of GenAI as we delve into the intricacies of Apache NiFi and its capabilities. Learn how this tool can significantly simplify the data engineering workflow for GenAI applications, allowing you to focus on the creative aspects rather than the technical complexities. I will guide you through practical examples and use cases, showing the impact of automation on prompt building. From data ingestion to transformation and delivery, witness how Apache NiFi streamlines the entire pipeline, ensuring a smooth and hassle-free experience.
Timothy Spann
https://www.youtube.com/@FLaNK-Stack
https://medium.com/@tspann
https://www.datainmotion.dev/
milvus, unstructured data, vector database, zilliz, cloud, vectors, python, deep learning, generative ai, genai, nifi, kafka, flink, streaming, iot, edge
Analysis insight about a Flyball dog competition team's performance
Insight of my analysis about a Flyball dog competition team's last year performance. Find more: https://github.com/rolandnagy-ds/flyball_race_analysis/tree/main
办(uts毕业证书)悉尼科技大学毕业证学历证书原版一模一样
原版一模一样【微信：741003700 】【(uts毕业证书)悉尼科技大学毕业证学历证书】【微信：741003700 】学位证，留信认证（真实可查，永久存档）offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。
本公司拥有海外各大学样板无数，能完美还原海外各大学 Bachelor Diploma degree, Master Degree Diploma
1:1完美还原海外各大学毕业材料上的工艺：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。文字图案浮雕、激光镭射、紫外荧光、温感、复印防伪等防伪工艺。材料咨询办理、认证咨询办理请加学历顾问Q/微741003700
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
一比一原版(Coventry毕业证书)考文垂大学毕业证如何办理
毕业原版【微信:41543339】【(Coventry毕业证书)考文垂大学毕业证】【微信:41543339】成绩单、外壳、offer、留信学历认证（永久存档真实可查）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
【我们承诺采用的是学校原版纸张（纸质、底色、纹路），我们拥有全套进口原装设备，特殊工艺都是采用不同机器制作，仿真度基本可以达到100%，所有工艺效果都可提前给客户展示，不满意可以根据客户要求进行调整，直到满意为止！】
【业务选择办理准则】
一、工作未确定，回国需先给父母、亲戚朋友看下文凭的情况，办理一份就读学校的毕业证【微信41543339】文凭即可
二、回国进私企、外企、自己做生意的情况，这些单位是不查询毕业证真伪的，而且国内没有渠道去查询国外文凭的真假，也不需要提供真实教育部认证。鉴于此，办理一份毕业证【微信41543339】即可
三、进国企，银行，事业单位，考公务员等等，这些单位是必需要提供真实教育部认证的，办理教育部认证所需资料众多且烦琐，所有材料您都必须提供原件，我们凭借丰富的经验，快捷的绿色通道帮您快速整合材料，让您少走弯路。
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
留信网服务项目：
1、留学生专业人才库服务（留信分析）
2、国（境）学习人员提供就业推荐信服务
3、留学人员区块链存储服务
→ 【关于价格问题（保证一手价格）】
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
选择实体注册公司办理，更放心，更安全！我们的承诺：客户在留信官方认证查询网站查询到认证通过结果后付款，不成功不收费！
Recently uploaded (20)
ViewShift: Hassle-free Dynamic Policy Enforcement for Every Data Lake
ViewShift: Hassle-free Dynamic Policy Enforcement for Every Data Lake
Predictably Improve Your B2B Tech Company's Performance by Leveraging Data
Predictably Improve Your B2B Tech Company's Performance by Leveraging Data
Beyond the Basics of A/B Tests: Highly Innovative Experimentation Tactics You...
Beyond the Basics of A/B Tests: Highly Innovative Experimentation Tactics You...
University of New South Wales degree offer diploma Transcript
University of New South Wales degree offer diploma Transcript
Udemy_2024_Global_Learning_Skills_Trends_Report (1).pdf
Udemy_2024_Global_Learning_Skills_Trends_Report (1).pdf
Intelligence supported media monitoring in veterinary medicine
Intelligence supported media monitoring in veterinary medicine
End-to-end pipeline agility - Berlin Buzzwords 2024
End-to-end pipeline agility - Berlin Buzzwords 2024
Analysis insight about a Flyball dog competition team's performance
Analysis insight about a Flyball dog competition team's performance
Pharmaceutical Drug Bids
- 1. PRIVATE & CONFIDENTIAL Increased the win percentage by 13% and the margin by 3.5% on average for bids related to generic drugs. DATAX > DEVELOPX > DEPLOYX CHALLENGE ACTION The client participates in bidding processes with hospitals and other healthcare providers that purchase their generic medications. The pharmaceutical company sought a means of winning more bids through AI, which could potentially make accurate market predictions, taking into account geographic and economic factors. DATAX Filtered the data for molecules that were in focus, reducing the number of actual bids to 15,809 from over 90,000. Bids that involved SKUs the client was not interested in were eliminated. DEVELOPX Used predictive modeling to understand the dynamics of pricing strategies of vendors for different molecules in different markets. Built a predictive model to determine winning bid price for products after LOE (Loss of Exclusivity) for different geographies/countries (identified by account, province, region). DEPLOYX Added additional features for specific regional markets and maintained models for use over time. PHARMACEUTICALS DATA USED BIDS 1